Target intelligence / Profile preview

Calpain-3 (CAPN3)

Target
CAPN3
Molecular classification
Enzyme, Cysteine protease, Member of the Calpain family (Calpain-3 belongs to the calpain superfamily, a group of calcium-dependent, non-lysosomal cysteine proteases)
01

Overview

Calpain-3 (CAPN3) is a muscle-specific, calcium-dependent cysteine protease essential for normal skeletal muscle function. It is unique among calpains due to its rapid self-autolysis and presence of specific insertion sequences (NS, IS1, IS2). CAPN3 is predominantly localized in the sarcomere, the basic contractile unit of muscle fibers, and is tightly regulated both by its own inhibitory fragments and interactions with sarcomeric proteins. CAPN3 regulates cytoskeletal remodeling, proteolytic turnover of structural proteins, and protein sumoylation, affecting muscle repair and maintenance. Mutations in the CAPN3 gene cause limb-girdle muscular dystrophy type 2A (LGMD2A), characterized by progressive weakness and wasting of the shoulder and pelvic girdle muscles. Despite its clear genetic link to disease, the endogenous substrates and precise medicine-relevant pathways of CAPN3 remain incompletely characterized, and no drugs specifically target this protease to date.

Other names
Calpain-3CAPN3p94CANP3CANPL3NCL1nCL-1Calcium-activated neutral proteinase 3Calpain L3Calpain p94Muscle-specific calcium-activated neutral protease 3New calpain 1LGMD2LGMD2ALGMDD4LGMDR1
02

Biological functions

Muscle cytoskeletal remodelingProteolysis (protein degradation)Regulation of protein sumoylationRegulation of apoptosisVesicle trafficking
03

Disease associations

Muscular dystrophy (specifically Limb-girdle muscular dystrophy type 2A, LGMD2A, also known as calpainopathy)
04

Safety considerations

Loss-of-function mutations cause muscle degenerationDysfunction of CAPN3 leads to progressive muscle weakness due to altered muscle remodeling and degradationRapid autolysis and instability make it challenging for therapeutic manipulation
05

Biomarkers

Mutations in CAPN3 gene as diagnostic markers for LGMD2A

Beyond the preview

Go deeper on Calpain-3 (CAPN3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calpain-3 (CAPN3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call